Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial

Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial

Introduction Recent results from Phase 3 clinical trials with cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) have shown that a monthly regimen is non-inferior to daily oral antiretroviral therapy (ART). Additional insights are necessary to prepare for LA ART roll-out, including identifyin...

Full description

Bibliographic Details
Main Authors: Miranda Murray, Deanna Kerrigan, Krischan J. Hudson, Nicola Walters, Tahilin Sanchez Karver, Andrea Mantsios, Noya Galai
Format: Article
Language:English
Published: Taylor & Francis Group 2020-10-01
Series:HIV Research & Clinical Practice
Subjects:
hiv
long-acting
survey
clinical trial
Online Access:http://dx.doi.org/10.1080/25787489.2020.1824718

Internet

http://dx.doi.org/10.1080/25787489.2020.1824718

Similar Items